India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Tuberculosis spread in children Experts in this field say that the tuberculosis situation in Nepal is becoming dire because the active model of identifying tuberculosis patients in villages cannot be implemented. A 9-year-old girl was admitted to Kanti Children's Hospital. The parents had taken the child to four private hospitals after experiencing fever, occasional fainting, and flatulence, but the disease was not diagnosed. In the end, he suspected that he might have tuberculosis and administered medicine. The health condition of the girl became serious as she sometimes took and stopped taking medicine. Child respiratory and intensive care specialist Dr. Jagatjivan went to Ghimire. He suspected that the girl had tuberculosis and suggested to be tested. After a few days of testing, it was confirmed that he had tuberculosis. He came in a very serious condition. Tuberculosis had already affected various organs. Ghimire said, "He had to be treated in the ICU for three weeks....